| pubmed-article:15491292 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0024301 | lld:lifeskim |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0242793 | lld:lifeskim |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15491292 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:15491292 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15491292 | pubmed:dateCreated | 2004-10-19 | lld:pubmed |
| pubmed-article:15491292 | pubmed:abstractText | Myeloablative allogeneic bone marrow transplantation (BMT) may be curative in patients with follicular non-Hodgkin's lymphoma, however, the impact of this therapy on long-term survival, disease progression and functional status is less clear. Twenty-nine patients (median age 42 years, range: 20-53) with advanced stage follicular lymphoma proceeded to allogeneic BMT a median of 25 (range: 8-154) months postdiagnosis, between 1985 and 2001, and have been followed for a minimum of 2 years. Eleven of 29 (38%) had refractory disease (n = 5 induction failure, n = 6 resistant relapse). Most (27 of 29, 93%) received total body irradiation-based conditioning; stem cell source was marrow from a related donor (n = 20) or unrelated donor (n = 9). Seventeen of 29 patients (59%) were alive a median of 5 years (range: 2-11) post-BMT with a median Karnofsky Performance Score of 100%. Death occurred because of transplant complications in seven patients (cumulative incidence of non-relapse mortality 24%), and progressive lymphoma in five patients (cumulative incidence of refractory/recurrent lymphoma 23%). The 5-year probability of overall and event-free survival was 58% and 53% respectively. Allogeneic BMT has resulted in long-term disease-free survival for approximately 50% of this cohort of patients with advanced follicular lymphoma and most of them now enjoy robust health. | lld:pubmed |
| pubmed-article:15491292 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15491292 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15491292 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15491292 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15491292 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:15491292 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:SutherlandHea... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:GascoyneRandy... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:ConnorsJoseph... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:HoggeDonna... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:BarnettMichae... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:NantelStephen... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:NevillThomas... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:ShepherdJohn... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:TozeCynthia... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:SongKevin WKW | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:ForrestDonna... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:LavoieJulye... | lld:pubmed |
| pubmed-article:15491292 | pubmed:author | pubmed-author:VossNicholas... | lld:pubmed |
| pubmed-article:15491292 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15491292 | pubmed:volume | 127 | lld:pubmed |
| pubmed-article:15491292 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15491292 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15491292 | pubmed:pagination | 311-21 | lld:pubmed |
| pubmed-article:15491292 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:meshHeading | pubmed-meshheading:15491292... | lld:pubmed |
| pubmed-article:15491292 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15491292 | pubmed:articleTitle | Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. | lld:pubmed |
| pubmed-article:15491292 | pubmed:affiliation | Division of Hematology, Leukemia/BMT Program of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, British Columbia, Canada. ctoze@bccancer.bc.ca | lld:pubmed |
| pubmed-article:15491292 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15491292 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
